Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2017-11-24
Buyer: Oslo universitetssykehus HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 1164800 NOK

Technical requirements: Oslo Universitetssykehus HF [Oslo University Hospital], Barne og Ungdomsklinikken [the Department of Paediatrics] shall procure a Q-PCR for newborn screening, diagnostics and patient monitoring.
The newborn screening has a national treatment service for screening of approx. 60 000 newborns per year for 23 severe congenital diseases, diagnostics and follow-up of patients with PKU.
Oslo Universitetssykehus HF [Oslo University Hospital], Barne og Ungdomsklinikken [the Department of Paediatrics] shall procure a Q-PCR for newborn screening, diagnostics and patient monitoring.
The newborn screening has a national treatment service for screening of approx. 60 000 newborns per year for 23 severe congenital diseases, diagnostics and follow-up of patients with PKU.
— Quant Studio 7 is the only Q-PCR instrument that can run TLDA block/TAC block (TaqMan Array Card block). The TDLA block will be used in the already existing equipment.
— Taq man Array card block allows small volume 1 ul- i.e. 50 ul per port and only 400 ul per card (384 samples). The pre-designed card involves less individual differences which in turn streamlines the time.
— The new Q-PCR instrument will, together with the existing instrument, be back-up for each other. It is important that the new instrument has the same requirements as the existing instrument in regard to established analyses, compatibility, algorithms and accreditation.
This is based on Thermo Fischer Scientific Norge AS being the only supplier that can perform the delivery, due to technical reasons. Terms of the PPR § 5-2 are considered fulfilled.
The procurement's value includes the procurement of equipment specific consumables for as long as the instrument is in use, as well as the value of a full service contract for the instrument's lifetime.
Oslo Universitetssykehus HF [Oslo University Hospital], Barne og Ungdomsklinikken [the Department of Paediatrics] shall procure a Q-PCR for newborn screening, diagnostics and patient monitoring.
The newborn screening has a national treatment service for screening of approx. 60 000 newborns per year for 23 severe congenital diseases, diagnostics and follow-up of patients with PKU.
— Quant Studio 7 is the only Q-PCR instrument that can run TLDA block/TAC block (TaqMan Array Card block). The TDLA block will be used in the already existing equipment.
— Taq man Array card block allows small volume 1 ul- i.e. 50 ul per port and only 400 ul per card (384 samples). The pre-designed card involves less individual differences which in turn streamlines the time.
— The new Q-PCR instrument will, together with the existing instrument, be back-up for each other. It is important that the new instrument has the same requirements as the existing instrument in regard to established analyses, compatibility, algorithms and accreditation.
This is based on Thermo Fischer Scientific Norge AS being the only supplier that can perform the delivery, due to technical reasons. Terms of the PPR § 5-2 are considered fulfilled.


Winner: Thermo Fisher Scientific
Award value: 1164800